Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals

Human Immunology

Volumn 55, Issue 1, 1997, Pages 39-45

  Stassi, Giorgio ^a,b   Todaro, Matilde ^a   De Maria, Ruggero ^a   Candore, Giuseppina ^b   Cigna, Diego ^b   Caruso, Calogero ^b   Galluzzo, Aldo ^a   Giordano, Carla ^a  

^a Institute of Clinical Medicine   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; HLA B8 ANTIGEN; HLA DR3 ANTIGEN;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; FEMALE; FLOW CYTOMETRY; HLA TYPING; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MOLECULAR INTERACTION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD14; ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, CD95; APOPTOSIS; B-LYMPHOCYTES; FLOW CYTOMETRY; HISTOCOMPATIBILITY TESTING; HLA-B8 ANTIGEN; HLA-DR3 ANTIGEN; HUMANS; T-LYMPHOCYTES;

EID: 0030930144     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(97)00072-4     Document Type: Article

References (34)

1. Nagata S, Golstein P: The Fas death factor. Science 267: 1449, 1995.
2. Krammer PH, Dhein J, Walczak H, Berhmann G, Mariani S, Matiba M, Daniel P, Knipping E, Westemdorp MO, Striker K, Baumler C, Heebardt S, Germer M, Peter ME, Debatin KM: The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 142:175, 1994.
3. Abbas AK: Die and let live: Eliminating dangerous lymphocytes. Cell 84:655, 1996.
4. Mountz JD, Zhou T, Su X, Wu J, Cheng J: The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune disease. Clin Immunol Immunopathol 80:S2, 1996.
5. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233, 1991.
6. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301, 1989.
7. Brunner T, Mogil RJ, La Face D, Yoo NJ, Mahboudi A, Echeverri F, Martin SJ, Force WR, Lynch DH, Ware CF, Green DR: Cell-autonomous Fas (CD95)/Fas ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441, 1995.
8. Carter BD, Kaltschimidt C, Kaltschimidt B, Offennauser N, Bohm-Mattaei R, Baeuerle PA, Barde YA: Selective activation of NK-KB by nerve growth factor through the neurotropin receptor p75. Science 272:542, 1996.
9. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH: Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 373:438, 1995.
10. Muzio M, Chimaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Scaffioli C, Bretz JD, Zhang M, Ni J, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (FAS-APO-1) death-inducing signaling complex. Cell 85:817, 1996.
11. Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R: Apoptotic signaling through CD95 (Fas/APO-1) activates an acidic sphingo-myelinase. J Exp Med 177:1547, 1994.
12. Wiegmann K, Schutze S, Machleidt T, Witte D, Kronke M: Functional dichotomy of neutral and acidic sphingo-myelinases in tumor necrosis factor signaling. Cell 78: 1005, 1994.
13. Modica MA, Colucci AT, Candore G, Caruso C: The HLA-B8, DR3 haplotype and immune response in healthy subjects. Immunol Infect Dis 3:119, 1993.
14. Cryan EM, Stevens FM, Skehill R, Bourke M, Grimes H, McCarthy CF: Immunoglobulins in healthy controls: HLA-B8 and sex differences. Tissue Antigens 26:254, 1985.
15. Bishof NA, Welch TR, Beischel LS, Carson D, Donnelly PA: DP polymorphism in HLA-A1,-B8,-DR3 extended haplotype associated with the membranoproliferative glomerular nephritis and systemic lupus erythematosus. Pediatr Nephrol 7:243, 1993.
16. Candore G, Cigna D, Gervasi G, Colucci AT, Modica MA, Caruso C: In vitro cytokine production by HLA-B8, DR3 positive subjects. Autoimmunity 18:121, 1994.
17. Candore G, Colucci AT, Modica MA, Caruso C: HLA-B8, DR3 T cell impairment is completely restored with in vitro treatment with interleukin-2. Immunopharmacol Immunotoxicol 13:551, 1991.
18. Caruso C, Candore G, Colucci AT, Cigna V, Modica MA, Tantillo G, Salerno A: Natural killer and lymphokine-activated killer activity in HLA-B8, DR3 positive subjects. Hum Immunol 38:226, 1993.
19. Giordano C, De Maria R, Stassi G, Todaro M, Richiusa P, Giordano M, Testi R, Galluzzo A: Defective expression of the apoptosis-inducing CD95 (Fas/APO-1) molecule on T and B cells in IDDM. Diabetologia 38:1449, 1995.
20. Gmelig-Meyling F, Dawisha S, Steinberg AD: Assessment of in vivo frequency of mutated T cells in patients with systemic lupus erythematosus. J Exp Med 175:297, 1992.
21. Nicoletti I, Migliorati G, Pagliacci MS, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide and flow cytometry. J Immunol Methods 139:271, 1991.
22. Castro JE, Listman JA, Jacobson BA, Wang Y, Lopez PA, Ju S, Finn PW, Perkins DL: Fas modulation of apoptosis during negative selection of thymocytes. Immunity 5: 617, 1996.
23. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bangasco M, Testi R, Galluzzo A: Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 275:960, 1997.
24. Green DR, Scott DW: Activation-induced apoptosis in lymphocytes. Curr Opin Immunol 6:476, 1994.
25. Adachi M, Watanabe-Fukunaga R, Nagata S: Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci USA 90:1756, 1993.
26. Wu J, Zhou T, Zhang J, Mountz JD: Correction of autoimmune disease in CD2-Fas transgenic mice. Proc Natl Acad Sei USA 91:2344, 1994.
27. Kallenberg CG, Klaassen RJ, Westra J, Beelen JM, Ockhuizen T: Immunoglobulin genes HLA-B8/DR3 and immunoresponsiveness to primary immunogen and mitogens in normal subjects. Clin Immunol Immunopathol 47:333, 1988.
28. Candore G, Cigna D, Todaro M, De Maria R, Stassi G, Giordano C, Caruso C: T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro. Hum Immunol 42:289, 1995.
29. Modica MA, Di Lorenzo G, Galluzzo A, Giordano C, Portelli MR, Candore G, Caruso C: Soluble interleukin-2 receptor secretion defect in vitro in HLA-B8, DR3 positive subjects. Autoimmunity 7:87, 1990.
30. Lio D, D'Anna C, Gervasi F, Cigna D, Modica MA, Candore G, Caruso C: In vitro impairment of interleukin-5 production in HLA-B8, DR3-positive individuals: Implications for immunoglobulin A synthesis dysfunction. Hum Immunol 44:170, 1995.
31. Hashimoto S, Michalski JP, Berman MA, McCombs C: Mechanism of a lymphocyte abnormality associated with HLA-B8-DR3: role of interleukin-1. Clin Exp Immunol 79:227, 1990.
32. Candore G, Di Lorenzo G, Cigna D, Colucci AT, Modica MA, Caruso C: γ-Interferon, interleukin-4 and interleukin-6 in vitro production in old subjects. Autoimmunity 16:275, 1993.
33. Steel CM, Ludlam CA, Beatson D, Peutherer JF, Cuthbert RJF, Simmonds P, Morrison H, Jones M: HLA haplotype A1, B8, DR3 as a risk factor for HIV-related disease. Lancet 1:1185, 1988.
34. Testi R: Sphingomyelin breakdown and cell fate. Trends Biochem Sci 21:464, 1996.